Stacytine 200

Stacytine 200 is an expectorant drug used for patients with a lot of phlegm. The medicine has the effect of a mucolytic-type mucomodifier.

Pack size Box of 01 tube of 10 tablets. Box of 4 strips x 4 tablets
Shelf-life 24 months
Composition Acetylcysteine
Dosage forms and strengths Effervescent tablet: 200 mg
Product code :



  • Treatment of bronchial secretion disorders, in particular during acute bronchial affections: Acute bronchitis and acute episode of chronic bronchopneumopathy.


  • Adults and children over 7 years old: 1 tablet 3 times a day.
  • Children from 2 to 7 years old: 1 tablet (200 mg) twice a day.
  • The duration of treatment will not exceed 8 to 10 days without medical advice.


  • Administered orally. Dissolve the effervescent tablet in half a glass of water.
  • Hypersensitivity to acetylcysteine or to any of the ingredients.
  • Infant under 2 years of age.
  • Risk of bronchial congestion especially in infants and in some patients unable to effectively sputum.
  • Allergic skin reactions such as pruritus, rash erythematous, urticaria and angioedema.
  • Possibility of digestive intolerance phenomena (gastric pain, nausea, diarrhea). It is advisable to reduce the dose.
  • The association of bronchial mucomodifiers with cough suppressants and/or secretion-drying substances (atropine) is irrational.
  • Mucolytics should not be used in infants.
  • Treatment should be reassessed if symptoms or pathology persist or worsen.
  • Stacytine 200 contains sorbitol. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.
  • Stacytine 200 contains aspartame, may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
  • Stacytine 200 contains sodium benzoate which may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).
  • Caution is advised in subjects with peptic ulcer disease.
  • The use of acetylcysteine should only be considered during pregnancy if necessary.
  • Breastfeeding is possible during acetylcysteine administration.
  • Patients should be aware of how they react to drug before driving or operating machinery.